Evolus (NASDAQ:EOLS) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Evolus (NASDAQ:EOLS) in a research note issued to investors on Thursday morning, Benzinga reports.

Several other research analysts have also recently weighed in on EOLS. HC Wainwright reaffirmed a buy rating and issued a $27.00 price target on shares of Evolus in a report on Tuesday, May 21st. Needham & Company LLC reaffirmed a buy rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday, May 8th.

Evolus Trading Up 1.2 %

Shares of EOLS stock opened at $10.77 on Thursday. The company’s fifty day simple moving average is $12.28 and its two-hundred day simple moving average is $12.32. The company has a debt-to-equity ratio of 6.54, a current ratio of 3.21 and a quick ratio of 2.96. Evolus has a 1 year low of $7.07 and a 1 year high of $15.43. The stock has a market capitalization of $674.20 million, a price-to-earnings ratio of -10.26 and a beta of 1.32.

Evolus (NASDAQ:EOLS) last issued its earnings results on Tuesday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The business had revenue of $59.33 million for the quarter, compared to analyst estimates of $58.78 million. As a group, analysts anticipate that Evolus will post -0.61 earnings per share for the current year.

Insider Buying and Selling

In related news, insider David Moatazedi sold 16,051 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $12.72, for a total value of $204,168.72. Following the completion of the transaction, the insider now directly owns 673,563 shares in the company, valued at $8,567,721.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Sandra Beaver sold 2,423 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $12.72, for a total value of $30,820.56. Following the completion of the transaction, the chief financial officer now directly owns 151,778 shares in the company, valued at $1,930,616.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Moatazedi sold 16,051 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $12.72, for a total transaction of $204,168.72. Following the completion of the transaction, the insider now owns 673,563 shares of the company’s stock, valued at $8,567,721.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 191,131 shares of company stock worth $2,471,151. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Several institutional investors have recently added to or reduced their stakes in EOLS. China Universal Asset Management Co. Ltd. boosted its position in Evolus by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,614 shares of the company’s stock valued at $70,000 after buying an additional 5,155 shares during the period. AJOVista LLC purchased a new stake in Evolus during the fourth quarter valued at about $70,000. Tradition Wealth Management LLC boosted its position in Evolus by 44.8% during the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock valued at $84,000 after buying an additional 2,475 shares during the period. Sierra Summit Advisors LLC purchased a new stake in Evolus during the fourth quarter valued at about $119,000. Finally, Teza Capital Management LLC purchased a new stake in Evolus during the third quarter valued at about $136,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.